Home LiteratureArticle Details
PMID: 8549420 Published · ppublish English Journal Article Review

Quinolone activity against anaerobes: microbiological aspects.

Drugs ·Vol. 49 Suppl 2 ·1995-00-00 ·Pages 76-80

Appelbaum PC

Abstract

Currently available quinolones are either inactive or marginally active against anaerobic bacteria. This review summarises the in vitro activity of currently available as well as experimental quinolones against clinically significant anaerobic bacteria. Quinolones with low activity against anaerobes include ciprofloxacin, ofloxacin, levofloxacin, fleroxacin, pefloxacin, enoxacin, lomefloxacin and probably E 4868 and NM 441. Compounds with intermediate anaerobe activity include sparfloxacin, grepafloxacin, PD 131628 and AM 1155. Quinolones that are very active against anaerobes include clinafloxacin and DU 6859a. CP 99,219, a naphthyridone, is also very active against anaerobes. Toxicity problems have necessitated the withdrawal of some quinolones shown to have intermediate activity (temafloxacin and tosufloxacin) and the discontinuation of the development of some investigational agents (Win 57273 and BAY Y 3118) with high activity. Conclusions regarding the therapeutic value of quinolones against human anaerobic infections await further clinical toxicological and pharmacokinetic studies.

MeSH Terms
4-Quinolones Anti-Infective Agents/pharmacology Bacteria, Anaerobic/drug effects Microbial Sensitivity Tests
Chemicals
4-Quinolones Anti-Infective Agents
Authors & Affiliations
1 authors, click to expand affiliations / ORCID
Appelbaum P C
Department of Pathology, Hershey Medical Center, Pennsylvania, USA.
References (33)
33 references, click to expand
  1. Methods for testing the susceptibility of anaerobic bacteria to two fluoroquinolone compounds, PD 131628 and clinafloxacin.
    J Antimicrob Chemother. 1993 Jun;31(6):893-900 PMID: 8395494
  2. In-vitro activity of enoxacin (CL-919), a new quinoline derivative, compared with that of other antimicrobial agents.
    J Antimicrob Chemother. 1984 Mar;13(3):237-44 PMID: 6586712
  3. Beta-lactamase production, beta-lactam sensitivity and resistance to synergy with clavulanate of 737 Bacteroides fragilis group organisms from thirty-three US centres.
    J Antimicrob Chemother. 1990 Sep;26(3):361-70 PMID: 2228827
  4. Susceptibility of anaerobic bacteria isolated from intra-abdominal infections to ofloxacin and interaction of ofloxacin with metronidazole.
    Antimicrob Agents Chemother. 1991 Nov;35(11):2447-9 PMID: 1804024
  5. Beta-lactamase production and susceptibilities to amoxicillin, amoxicillin-clavulanate, ticarcillin, ticarcillin-clavulanate, cefoxitin, imipenem, and metronidazole of 320 non-Bacteroides fragilis Bacteroides isolates and 129 fusobacteria from 28 U.S. centers.
    Antimicrob Agents Chemother. 1990 Aug;34(8):1546-50 PMID: 2221864
  6. Bactericidal activity of sparfloxacin and ciprofloxacin under anaerobic conditions.
    J Antimicrob Chemother. 1991 Sep;28(3):399-405 PMID: 1660046
  7. In vitro activities of a dual-action antibacterial agent, Ro 23-9424, and comparative agents.
    Antimicrob Agents Chemother. 1989 Jul;33(7):1072-7 PMID: 2782857
  8. In-vitro activity of temafloxacin against anaerobic bacteria: a comparative study.
    J Antimicrob Chemother. 1991 Dec;28 Suppl C:25-30 PMID: 1664827
  9. In vitro activities of sparfloxacin, tosufloxacin, ciprofloxacin, and fleroxacin.
    Antimicrob Agents Chemother. 1991 May;35(5):955-60 PMID: 1906696
  10. Antibacterial activity of NM394, the active form of prodrug NM441, a new quinolone.
    Antimicrob Agents Chemother. 1993 Apr;37(4):793-800 PMID: 8388199
  11. Reduction of oral flora with ciprofloxacin in healthy volunteers.
    J Antimicrob Chemother. 1988 Feb;21(2):243-9 PMID: 3360683
  12. Comparative in vitro activities of a new quinolone, WIN 57273, and piperacillin plus tazobactam against anaerobic bacteria.
    Antimicrob Agents Chemother. 1990 Sep;34(9):1858-61 PMID: 2178340
  13. Comparative activity of the quinolones against anaerobic bacteria isolated at community hospitals.
    Antimicrob Agents Chemother. 1985 Apr;27(4):657-9 PMID: 3847273
  14. In vitro antimicrobial activity of CP-99,219, a novel azabicyclo-naphthyridone.
    Antimicrob Agents Chemother. 1993 Feb;37(2):349-53 PMID: 8043036
  15. Mechanisms of beta-lactam resistance in anaerobic bacteria.
    Rev Infect Dis. 1986 Nov-Dec;8 Suppl 5:S543-8 PMID: 3541135
  16. In vitro activity of E-4868, a new trifluoroquinolone, compared to six similar compounds.
    Eur J Clin Microbiol Infect Dis. 1993 Feb;12(2):134-41 PMID: 8388792
  17. Susceptibilities of 428 gram-positive and -negative anaerobic bacteria to Bay y3118 compared with their susceptibilities to ciprofloxacin, clindamycin, metronidazole, piperacillin, piperacillin-tazobactam, and cefoxitin.
    Antimicrob Agents Chemother. 1993 Aug;37(8):1649-54 PMID: 8215278
  18. In vitro and in vivo antibacterial activities of E-4868, a new fluoroquinolone with a 7-azetidin ring substituent.
    Antimicrob Agents Chemother. 1993 Apr;37(4):868-74 PMID: 8388202
  19. Comparative activity of ciprofloxacin, ofloxacin, sparfloxacin, temafloxacin, CI-960, CI-990, and WIN 57273 against anaerobic bacteria.
    Antimicrob Agents Chemother. 1992 May;36(5):1158-62 PMID: 1324640
  20. In vitro activity of lomefloxacin (SC-47111; NY-198), a difluoroquinolone 3-carboxylic acid, compared with those of other quinolones.
    Antimicrob Agents Chemother. 1988 May;32(5):656-62 PMID: 3164987
  21. Activity of fleroxacin alone and in combination with clindamycin or metronidazole in experimental intra-abdominal abscesses.
    Antimicrob Agents Chemother. 1994 Feb;38(2):252-5 PMID: 8192453
  22. Susceptibilities of 540 anaerobic gram-negative bacilli to amoxicillin, amoxicillin-BRL 42715, amoxicillin-clavulanate, temafloxacin, and clindamycin.
    Antimicrob Agents Chemother. 1992 May;36(5):1140-3 PMID: 1324639
  23. Susceptibility of 539 gram-positive and gram-negative anaerobes to new agents, including RP59500, biapenem, trospectomycin and piperacillin/tazobactam.
    J Antimicrob Chemother. 1993 Aug;32(2):223-31 PMID: 8226424
  24. Comparative in vitro activity of cefetamet and fleroxacin against anaerobic bacteria.
    Eur J Clin Microbiol. 1987 Dec;6(6):688-90 PMID: 3126062
  25. In vitro susceptibility of anaerobic bacteria to ciprofloxacin (Bay o 9867).
    Antimicrob Agents Chemother. 1984 Nov;26(5):785-6 PMID: 6517561
  26. Activity of CP 99,219 compared with those of ciprofloxacin, grepafloxacin, metronidazole, cefoxitin, piperacillin, and piperacillin-tazobactam against 489 anaerobes.
    Antimicrob Agents Chemother. 1994 Oct;38(10):2471-6 PMID: 7840591
  27. Susceptibilities of 394 Bacteroides fragilis, non-B. fragilis group Bacteroides species, and Fusobacterium species to newer antimicrobial agents.
    Antimicrob Agents Chemother. 1991 Jun;35(6):1214-8 PMID: 1929264
  28. In-vitro and in-vivo potency of five new fluoroquinolones against anaerobic bacteria.
    J Antimicrob Chemother. 1986 Dec;18(6):693-701 PMID: 3818495
  29. In vitro activities of three of the newer quinolones against anaerobic bacteria.
    Antimicrob Agents Chemother. 1992 Jan;36(1):239-43 PMID: 1317149
  30. Comparative in-vitro activities of the new quinolone, Bay y 3118, and ciprofloxacin, sparfloxacin, tosufloxacin, CI-960 and CI-990.
    J Antimicrob Chemother. 1993 Apr;31(4):505-22 PMID: 7605398
  31. Activity of pefloxacin and thirteen other antimicrobial agents in vitro against isolates from hospital and genitourinary infections.
    J Antimicrob Chemother. 1986 Jun;17(6):739-46 PMID: 3460983
  32. In vitro and in vivo antibacterial activities of levofloxacin (l-ofloxacin), an optically active ofloxacin.
    Antimicrob Agents Chemother. 1992 Apr;36(4):860-6 PMID: 1503449
  33. The killing action of fleroxacin upon Bacteroides fragilis.
    J Antimicrob Chemother. 1989 Jan;23(1):53-8 PMID: 2501268
Article Info
Journal
Drugs
Abbr.
Drugs
ISSN
0012-6667
DOI
10.2165/00003495-199500492-00012
Published
1995-00-00
Pages
76-80
Language
English
Region
New Zealand
NLM ID
7600076
Subset
IM
External Links
PubMed source DOI: 10.2165/00003495-199500492-00012 View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2